IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis

Hong Yang, Kaichun Wu, Hongjie Zhang, Qin Owang, Yinlei Miao, Fang Gu, Naizhong Hu, Kaifang Zou, Jianqi Sheng, Jin Li, Ping Zheng, Yulan Liu, Junxia Li, Xiaodi Wang, Yongdong Wu, Yaozong Yuan, Chunxiao Chen, Yanhua Pang, Meihua Cui and Jiaming Qian

Abstract

Background: Cytomegalovirus (CMV) infection can significantly complicate and worsen the condition of acute severe ulcerative colitis (UC) patients. We aimed to explore the predictive risk factors to prevent and identify CMV infection at an early stage in acute UC patients.

Methods: A total of 115 moderate-to-severe active UC patients from 17 hospitals throughout China were enrolled. Active CMV infection was diagnosed by one of the following: CMV pp65 antigens, CMV IgM antibodies or CMV DNA. We identified the independent risk factors by multivariate analyses.

Results: A total of 64 of 115 active UC patients had active CMV infection. Compared to the non-CMV-infected patients, the CMV-infected patients had a tendency to be male and to exhibit abdominal pain; fever; oral ulcers; eosinopenia; low albumin, immunoglobulin (Ig) A, IgM, and IgG levels; increased high-sensitivity C-reactive protein (hsCRP) levels; hyponatremia; pancolonic lesions; initial onset type; severe activity; and glucocorticoid (high-dose) and immunosuppressive agent use ($P < 0.05$). In further multivariate analyses, the use of high-dose glucocorticoids (OR 13.55, 95% CI 2.49–73.61, $P < 0.01$) and immunosuppressive agents (OR 11.23, 95% CI 1.05–119.99, $P = 0.04$) were independent risk factors for CMV infection. A decrease eosinophil and albumin levels were risk factors for CMV infection. With every $0.1 \times 10^9/L$ decrease in the peripheral blood eosinophil level or $1 \text{g/L}$ decrease in the serum albumin level, the risk for CMV infection in UC patients increased by $5.21$-fold (1/0.192) or $1.19$-fold (1/0.839), respectively.

Conclusions: High-dose glucocorticoid and immunosuppressive agent treatment significantly increase the risk of CMV infection, and correcting eosinopenia and low albumin levels may help prevent CMV infection in UC patients.

Keywords: Ulcerative colitis, Cytomegalovirus, Glucocorticoid, Immunosuppressive agents, eosinophils
Instruction

Ulcereative colitis (UC), a type of nonspecific inflammation of the colon, is characterized by a chronic disease course and delayed healing. The morbidity and colectomy rates of UC patients have significantly decreased with the development and application of therapeutic drugs such as glucocorticoids and immunosuppressive agents. However, the use of these therapeutic drugs alone or in combination may increase the risk of opportunistic infections. In particular, it has been shown that cytomegalovirus (CMV) infection can complicate the condition or even increase the death rate of UC patients [1]. CMV, belonging to the herpesviridae family, remains latent after the initial infection and persists throughout the lifetime of the host. Indeed, patients with inflammatory bowel disease (IBD) are often immunosuppressed and severely malnourished, which may lead to a significantly increased risk of CMV reactivation [2]. Twenty-one to 34% of acute and severe UC patients are reportedly CMV-positive, and the active CMV infection rate among those who receive urgent colectomy for UC is 10–33.3% [3–7].

One study [8] showed that female gender, pancolic inflammatory disease and active inflammation upon histological examination were independent risk factors for CMV reactivation. However, few studies have focused on blood markers for predicting the risk of CMV infection in IBD patients. Such markers will be helpful for clinicians to monitor and improve the disease prognosis as well as to initiate early intervention strategies for preventing infection. The goal of this study was to fully understand CMV infection in Chinese patients with active UC and to identify the risk factors for CMV infection in IBD patients with different demographic characteristics.

Patients and methods

Patients

A total of 115 patients from 17 hospitals with moderate-to-severe active UC and CMV infection were enrolled in this study from 2009 to 2017. The diagnostic criteria, disease activity, and lesion extent were based on the European Crohn's and Colitis Organization (ECCO) guidelines [9] and the Consensus on the Diagnosis and Treatment of Inflammatory Bowel Disease (Beijing, 2018) [10]. All patients were diagnosed by clinical, endoscopic and histological studies. Disease severity was determined clinically by the Truelove and Witts’ score and endoscopically by the Mayo endoscopic score as previously described [11]. CMV infection was confirmed by blood pp65 antigens, CMV IgM antibodies and CMV qPCR. This study was approved by the Institutional Review Board of Peking Union Medical College Hospital.

Peripheral blood CMV detection

The diagnostic standard for active CMV infection was a positive result using one of the following methods: HCMV pp65 antigen (CMV pp65), CMV IgM, and CMV DNA quantitative polymerase chain reaction (qPCR) detection. HCMV pp65 antigen detection was performed using immunofluorescence staining (HCMV Brite kit, IQ, the Netherlands). Detection of peripheral blood IgM antibodies was achieved using an enzyme-linked immnosorbent assay (ELISA) (Captia Cytomegalovirus IgM, Trinity Biotech Plc, Ireland). Quantitation of HCMV DNA was based on real-time qPCR (an HCMV nucleic acid quantitative assay kit, DAAN Gene Co., Ltd. of Sun Yat-sen University, China). The cut-off value of CMV-DNA in diagnosing CMV infection was 500 copies/ml. CMV colitis was defined as the identification of characteristic intranuclear or intracellular inclusion bodies on H&E sections and/or identification of CMV-specific antigen by IHC from colonoscopy biopsy samples.

Steroid and immunosuppressive agents

The definitions of steroid and immunosuppressive agent application are described below [12]. The large steroid dose was defined as oral prednisone at ≥40 mg per day (qd). The moderate dose was defined as oral prednisone at ≥20 mg but < 40 mg qd for at least two months. The small dose was defined as oral prednisone at < 20 mg qd or oral prednisone at ≥20 mg qd for less than two months. The application of immunosuppressive agents was defined as the use of azathioprine, cyclosporin, or thalidomide in the past month.

Statistical methods

The clinical symptoms, Montreal classification, complications, and laboratory indicators of confirmed UC patients with or without CMV infection were retrospectively compared and analyzed. Statistical analyses were performed using SPSS 19.0 software for univariate and multivariate analyses. In univariate analyses, categorical variables were analyzed using the chi-square or Fisher’s exact test. Continuous variables following a normal distribution are presented as the mean (SD) and were analyzed by t test; otherwise, they are presented as median and interquartile ranges and were analyzed by the Mann-Whitney U test. Indicators at \( P < 0.05 \) were included in binary logistic regression for multivariate analyses. \( P < 0.05 \) indicated statistical significance.

Results

Baseline characteristics

Of 115 patients with confirmed active UC, 64 had active CMV infection. CMV-DNA was higher than 500 copies/ml in 56 cases (87.5%), CMV-PP65 was positive in 24
cases (37.5%) and CMV-IgM was positive in 13 cases (20.3%). CMV colitis was diagnosed in 39 cases (60.1%) based on identification of characteristic intranuclear or intracellular inclusion bodies on H&E sections and/or identification of CMV-specific antigen by IHC.

In the active CMV infection group, the male/female ratio was 41:23, and the mean age was 47.63 ± 13.71 years. For the non-CMV infection group, the male/female ratio was 21:30, with a mean age of 44.69 ± 15.28 years. Between the two groups, the male/female ratio was significantly different: more males were in the CMV infection group, while more females were in the non-CMV infection group (P < 0.05). Conversely, age at disease onset (43.91 ± 13.17 vs. 38.78 ± 14.57) and current admission (47.63 ± 13.71 vs. 44.69 ± 15.28) did not differ significantly between these two groups. The two groups did not present significant differences in the history of diabetes mellitus, appendectomy, smoking, or drinking or in the familiar history of IBD. The specific data are summarized in Table 1.

Comparison and analyses of clinical manifestations, complications, and laboratory tests between the active UC with and without active CMV infection groups

As shown in Table 2, the incidence rates of abdominal pain (78.1% vs. 60.8%, P = 0.043) and fever (56.3% vs. 29.4%, P = 0.005) in patients with active CMV infection were higher than those in the noninfection group. Regarding extra-intestinal manifestations, the incidence of oral ulcers in the infection group was higher than that in the noninfection group (21.9% vs. 2.0%, P = 0.002). Complications between the two groups were not significantly different.

With regard to laboratory tests, the rates of eosinopenia (0.2(0.1, 0.5) vs 0.8(0.4,2.5), P<0.001), hypoalbumina (30.09 ± 5.10 vs. 34.67 ± 6.61, P<0.001), low IgA (1.91(1.21,2.29) vs 2.30(1.83, 2.82), P = 0.011), low IgM (0.52(0.40,0.89) vs. 0.89 (0.68, 1.86), P = 0.002), low IgG (8.9 (6.28, 11.79) vs. 12.34 (9.40, 16.20), P = 0.001), high-sensitivity C-reactive protein (hsCRP) (42.67 (17.16, 74.65) vs. 9.92 (3.68, 37.71), P = 0.001), and hyponatremia (136.41 ± 3.70 vs. 138.42 ± 2.98, P = 0.001) in the active CMV infection group were higher than those in the noninfection group. The laboratory data are shown in Table 3.

**Comparison and analyses of disease patterns and drug administration conditions**

Compared with the non-CMV group, the active CMV infection group exhibited significantly more cases of E3 lesions, initial onset type, and severe disease (determined clinically by the Truelove and Witts’ score and endoscopically by the Mayo endoscopic score as previously described). The number of patients who used immunosuppressive agents or a large dose of steroids was significantly higher in the active CMV infection group than in the non-CMV infection group.

### Table 1 Baseline characteristics of patients in the CMV infection and non-CMV infection groups

| Indicator                  | CMV infection (n = 64) | Non-CMV infection (n = 51) | P   |
|----------------------------|------------------------|----------------------------|-----|
| Gender a                   |                        |                            | 0.014|
| Male                       | 41 (64.1%)             | 21 (41.2%)                 |     |
| Female                     | 23 (35.9%)             | 30 (58.8%)                 |     |
| Age at disease onset b     | 43.91 ± 13.17          | 38.78 ± 14.57              | 0.051|
| Age at current admission b | 47.63 ± 13.71          | 44.69 ± 15.28              | 0.280|
| Smoking a                  |                        |                            | 0.079|
| Yes                        | 22 (34.4%)             | 10 (19.6%)                 |     |
| No                         | 42 (65.6%)             | 41 (80.4%)                 |     |
| Drinking a                 |                        |                            | 0.734|
| Yes                        | 14 (22.2%)             | 10 (19.6%)                 |     |
| No                         | 49 (77.8%)             | 41 (80.4%)                 |     |
| IBD family history a      |                        |                            | 0.380|
| Yes                        | 4 (6.3%)               | 1 (2.0%)                   |     |
| No                         | 60 (93.7%)             | 50 (98.0%)                 |     |
| Appendectomy history a    |                        |                            | 0.502|
| Yes                        | 2 (3.1%)               | 0                          |     |
| No                         | 62 (96.9%)             | 51 (100%)                  |     |

*aChi-square test or Fisher’s exact test was used. b data are expressed as the mean ± SD and were determined by a t test. In the CMV infection group, the patient numbers for drinking do not add up to the total due to missing data*
| Variable                  | CMV infection (n = 64) | Non-CMV infection (n = 51) | P<sup>a</sup> |
|--------------------------|------------------------|-----------------------------|--------------|
| **Clinical manifestation** |                        |                             |              |
| Abdominal pain           |                        |                             |              |
| Yes                      | 50 (78.1%)             | 31 (60.8%)                  | 0.043        |
| No                       | 14 (21.9%)             | 20 (39.2%)                  |              |
| Stool frequency          | 9.7 ± 6.4              | 8.0 ± 4.7                   | 0.127        |
| Hematochezia             |                        |                             | 0.746        |
| Yes                      | 59 (92.2%)             | 45 (90.0%)                  |              |
| No                       | 5 (7.8%)               | 5 (10.0%)                   |              |
| Fever                    |                        |                             | 0.005        |
| Yes                      | 36 (56.3%)             | 15 (29.4%)                  |              |
| No                       | 28 (43.8%)             | 36 (70.6%)                  |              |
| **Parenteral presentations** |                      |                             |              |
| Oral ulcer               |                        |                             | 0.002        |
| Yes                      | 14 (21.9%)             | 1 (2.0%)                    |              |
| No                       | 50 (78.1%)             | 50 (98.0%)                  |              |
| Vulvar ulcer             |                        |                             | 1.000        |
| Yes                      | 1 (1.6%)               | 0                           |              |
| No                       | 63 (98.4%)             | 51 (100%)                   |              |
| Arthritis                |                        |                             | 0.115        |
| Yes                      | 6 (9.4%)               | 10 (19.6%)                  |              |
| No                       | 58 (90.6%)             | 41 (80.4%)                  |              |
| Gallstone                |                        |                             | 0.628        |
| Yes                      | 3 (4.7%)               | 1 (2.0%)                    |              |
| No                       | 61 (95.3%)             | 50 (98.0%)                  |              |
| Eye lesion               |                        |                             | 0.584        |
| Yes                      | 1 (1.6%)               | 2 (3.9%)                    |              |
| No                       | 63 (98.4%)             | 49 (96.1%)                  |              |
| Thromboembolism          |                        |                             | 0.321        |
| Yes                      | 1 (1.6%)               | 3 (5.9%)                    |              |
| No                       | 63 (98.4%)             | 48 (94.1%)                  |              |
| **Complications**        |                        |                             |              |
| Intestinal obstruction   |                        |                             | 1.000        |
| Yes                      | 3 (4.7%)               | 2 (3.9%)                    |              |
| No                       | 61 (95.3%)             | 49 (96.1%)                  |              |
| Intestinal perforation   |                        |                             | 1.000        |
| Yes                      | 1 (1.6%)               | 0                           |              |
| No                       | 63 (98.4%)             | 50 (100%)                   |              |
| Gastrointestinal bleeding|                        |                             | 0.380        |
| Yes                      | 4 (6.3%)               | 1 (2.0%)                    |              |
| No                       | 60 (93.7%)             | 50 (98.0%)                  |              |
| Toxic megacolon          |                        |                             | 1.000        |
| Yes                      | 1 (1.6%)               | 0                           |              |
| No                       | 63 (98.4%)             | 51 (100%)                   |              |

<sup>a</sup>Chi-square test or Fisher's exact test was used. In the non-CMV infection group, the patient numbers for hematochezia and intestinal perforation do not add up to the total due to missing data.
However, the two groups did not present significant differences in the use of biological agents; history of diabetes mellitus, appendectomy, smoking, or drinking; and familiar history of IBD. These results are compiled in Table 4.

**Multivariate analyses of independent risk factors for the development of active CMV infection in UC patients**

As shown in Table 5, high-dose steroid treatment and immunosuppressive agents were risk factors for CMV infection; i.e., the risk of active CMV infection in patients who used glucocorticoids at large doses and immunosuppressive agents were 13.55 and 11.23 times higher, respectively, than those in patients who did not receive these treatments. Conversely, increases in eosinophil and albumin levels were protective factors against CMV infection. With every $0.1 \times 10^8$/L increase in the peripheral blood eosinophil level, the risk of CMV infection in UC patients decreased by 80.8% ($1 - 0.192$). With every 1 g/L increase in the serum albumin level, the risk of CMV infection in UC patients decreased by 16.1% ($1 - 0.839$). IgA, IgG, IgM, C3 and C4 were not included in the multivariate model due to missing data.

**Discussion**

The association between CMV infection and UC has received increasing attention in recent years. The results of our previous study [13] showed that the development of CMV colitis due to CMV infection causes coloscopic changes in UC patients, presenting as punched-out and longitudinal ulcers. These changes draw increasing attention on the diagnosis and treatment of CMV infection and CMV colitis in active UC. Meanwhile, defective mucosal immunity, immunomodulator therapy

---

**Table 3** Analysis of laboratory tests between the CMV infection and non-CMV infection groups

| Variable               | CMV infection (n = 64) | Non-CMV infection (n = 51) | P       |
|------------------------|------------------------|---------------------------|---------|
| ASCAa                  |                        |                           |         |
| Positive               | 1 (4.3%)               | 2 (16.7%)                 | 0.266   |
| Negative              | 22 (95.7%)             | 10 (83.3%)                |         |
| ANCAa                  |                        |                           | 0.568   |
| Positive               | 19 (54.3%)             | 19 (59.4%)                |         |
| Negative              | 16 (45.7%)             | 13 (40.6%)                |         |
| WBC (10^9/L)           | 7.82 ± 3.04            | 7.70 ± 3.17               | 0.843   |
| Neu (10^9/L)           | 5.18 (3.58,6.94)       | 4.55 (3.36,6.9)           | 0.494   |
| Eos (10^8/L)           | 0.2 (0.1,0.5)          | 0.8 (0.4,2.5)             | <0.001  |
| LY (10^9/L)            | 1.67 (1.21,2.35)       | 1.68 (1.20,2.29)          | 0.968   |
| Hb (g/L)               | 103.06 ± 23.59         | 111.53 ± 23.27            | 0.057   |
| PLT (10^9/L)           | 293 (244,364)          | 294 (255,330)             | 0.802   |
| Albumin (g/L)          | 30.09 ± 5.10           | 34.67 ± 6.61              | <0.001  |
| Serum potassium (mmol/L)| 3.78 ± 0.36            | 3.73 ± 0.36               | 0.466   |
| Serum sodium (mmol/L)  | 136.41 ± 3.70          | 138.42 ± 2.98             | 0.001   |
| ALT (U/L)              | 15 (10,26.75)          | 10 (8,16.25)              | 0.008   |
| AST (U/L)              | 15 (11,19.25)          | 14.6 (11.20)              | 0.933   |
| GGT (U/L)              | 19 (15,38)             | 17.0 (11,22.5)            | 0.034   |
| ALP (U/L)              | 62 (51.75,71.25)       | 64 (54.5,87.5)            | 0.332   |
| IgA (g/L)              | 1.91 (1.21,2.29)       | 2.30 (1.83,2.82)          | 0.011   |
| IgM (g/L)              | 0.52 (0.40,0.89)       | 0.89 (0.68,1.86)          | 0.002   |
| IgG (g/L)              | 8.9 (6.28,11.79)       | 12.34 (9.40,16.20)        | 0.001   |
| C3 (g/L)               | 0.90 (0.71,1.03)       | 1.02 (0.76,1.25)          | 0.044   |
| C4 (g/L)               | 0.21 (0.16,0.24)       | 0.23 (0.15,0.28)          | 0.283   |
| ESR (mm/h)             | 36.0 (17.0,53.0)       | 27.0 (9.5,50.0)           | 0.119   |
| hsCRP (mg/L)           | 42.67 (17.16,74.65)    | 9.92 (3.68,37.71)         | <0.001  |

*Chi-square test or Fisher’s exact test was used. † data are expressed as the mean ± SD and were determined by a t test. & data are expressed by median and interquartile ranges and were determined by the Mann-Whitney U test. Patient numbers for the ASCA and ANCA tests do not add up to the total due to missing data

Note: ASCA anti-saccharomyces cerevisiae antibody, ANCA anti-neutrophil cytoplasmic antibodies, ESR erythrocyte sedimentation rate, CRP C response protein
Table 4 Analyses of risk factors between CMV infection and non-CMV infection

| Indicator                  | CMV infection (n = 64) | Non-CMV infection (n = 51) | P  |
|---------------------------|------------------------|---------------------------|----|
| Disease extent            |                        |                           |    |
| E1                        | 1 (1.6%)               | 1 (2.0%)                  |    |
| E2                        | 10 (16.1%)             | 17 (34.0%)                |    |
| E3                        | 51 (82.3%)             | 32 (64.0%)                |    |
| Disease severity          |                        |                           |    |
| Mild                      | 6 (9.7%)               | 8 (15.7%)                 |    |
| Moderate                  | 18 (29.0%)             | 28 (54.9%)                |    |
| Severe                    | 38 (61.3%)             | 15 (29.4%)                |    |
| Disease type              |                        |                           |    |
| Initial onset type        | 19 (30.6%)             | 5 (9.8%)                  |    |
| Chronic recurrence type   | 43 (69.3%)             | 46 (90.2%)                |    |
| Immunosuppressive agents  |                        |                           |    |
| Yes                       | 12 (18.8%)             | 3 (5.9%)                  |    |
| No                        | 52 (81.2%)             | 48 (94.1%)                |    |
| Steroid                   |                        |                           |    |
| No                        | 11 (17.2%)             | 33 (64.7%)                |    |
| Small dose                | 6 (9.4%)               | 12 (23.5%)                |    |
| Moderate dose             | 6 (9.4%)               | 2 (3.9%)                  |    |
| Large dose                | 41 (64.1%)             | 4 (7.8%)                  |    |
| IFX                       |                        |                           |    |
| Yes                       | 4 (6.3%)               | 0                         |    |
| No                        | 60 (93.7%)             | 51 (100%)                 |    |
| S-ASA                     |                        |                           |    |
| Yes                       | 56 (87.5%)             | 45 (88.2%)                |    |
| No                        | 8 (12.5%)              | 6 (11.8%)                 |    |

*Chi-square test or Fisher’s exact test was used. Some patient numbers do not add up to the total due to missing data.

Note: IFX infliximab

and malnutrition contribute to the risk of developing CMV infection in patients with moderate-to-severe active UC. To better understand the influence and risk factors of CMV infection in active UC, we performed a multicenter case-control study to assess the clinical symptoms, complications, biochemical indicators and effect of therapeutic drugs on the development of infection in patients with moderate-to-severe active UC. The results revealed prominent presentations of abdominal pain, fever, and oral ulcers after CMV infection, whereas the rates of gastrointestinal perforation, gastrointestinal bleeding, and toxic megacolon between the infection and noninfection groups did not appear significantly different. The probability of CMV infection induction increased with the use of glucocorticoids and immunosuppressive agents, whereas biological agents had no effect. Lower Ig levels and the initial onset type appeared more prominent in the CMV infection group than in the non-CMV infection group. Multivariate analysis showed that high-dose glucocorticoid treatment and immunosuppressive agents were independent risk factors for CMV infection, while low albumin and eosinophil levels were also risk factors for CMV infection in UC patients.

The major clinical manifestations of CMV infection are fatigue and fever. If the intestinal tract is involved, watery diarrhea, bloody stool, and abdominal pain might occur. This study analyzed the clinical characteristics of UC patients with and without CMV infection. The percentages of fever and abdominal pain in patients with CMV infection were significantly higher than those in

Table 5 Multivariate analyses

| Variable                  | OR     | 95% CI     | P   |
|---------------------------|--------|------------|-----|
| High-dose glucocorticoid  | 13.55  | 2.49–73.61 | 0.003|
| Immunosuppressive agent   | 11.23  | 1.05–119.99 | 0.045|
| Peripheral blood eosinophils | 0.192 | 0.048–0.763 | 0.019|
| Serum albumin             | 0.839  | 0.728–0.967 | 0.015|
patients without CMV infection, whereas no significant differences were observed in hematochezia and diarrhea incidence between the two groups. One possible reason for this result is that diarrhea and hematochezia are the major clinical manifestations for patients with active UC; therefore, significant differences between the two groups would be difficult to demonstrate.

With regard to complications, this study did not find significant differences in the proportions of complications between the CMV infection and noninfection groups. A recent study [14] reported that patients with CMV infection have a worse prognosis and are more prone to complications and increased colectomy rates than noninfected individuals. However, other studies did not support these results, possibly due to different inclusion criteria; for example, some studies enrolled patients with CMV infection, while others enrolled patients with CMV colitis. In addition, the results of this study indicated that patients with extensive colonic UC and severe UC are prone to CMV infection. These results were in accordance with extensive colonic UC and severe UC are prone to CMV infection. The hemoglobin level in the CMV infection group was decreased compared with the noninfection group. Although a significant increase in hsCRP, an inflammatory indicator, suggests that patients with severe inflammation activity are more prone to CMV infection. This result was consistent with the aforementioned results showing severe UC patients to be prone to CMV infection. The hemoglobin level in the CMV infection group also was decreased compared with that in the noninfection group. Although a significant P value was not obtained (P = 0.054), these results nonetheless indicate that CMV infection can aggravate the condition of UC patients. Furthermore, serum sodium levels in the CMV infection group were decreased, and there are two possible explanations for this result. First, the high inflammatory activity aggravated the disease, and diarrhea caused by CMV infection resulted in hyponatremia. The other explanation addresses diarrhea resulting in hyponatremia, which might be associated with CMV infection. It has been shown that [19] hyponatremia will result in cellular immune dysfunction, and abnormal cellular immunity probably promotes CMV infection.

The results of this study showed significant reductions in immunoglobulin (IgG, IgM, and IgA) levels in the CMV infection group. Immunoglobulins (Ig) comprise a group of globulins with immune functions that can interact with specific antigens, and studies [20, 21] have shown that hypoimmunoglobulinemia is closely associated with refractory CMV disease. A reduction in Ig levels can increase susceptibility to CMV infection and promote the occurrence and aggravation of CMV infection. CMV infection also affects the stability of immune function and the balance of T cell subsets, and the presence of lymphokine-activated killer (LAK) cells will significantly decrease the activity of natural killer (NK) cells and aggravate reductions in Ig levels [22]. Studies [23, 24] have shown that a reduction in serum Ig levels is common in adults and children with IBD, with one report [23] showing low IgG, IgG1, IgA, and IgM levels in 22.7, 23.4, 7.9, and 10.9% of IBD patients, respectively. IgAs, which are distributed on the surface of cells in the eyes and in the respiratory, gastrointestinal, and genitourinary tracts, are secretory lgs and the first-line defense against microorganisms. Although studies on the association between Ig and IBD are scarce, Zhou et al. [22] showed a significant reduction in serum IgA levels in patients infected with CMV in combination with other viruses. The results of this study suggest that attention should be paid to changes in Ig levels in research. Unfortunately, Ig was not included in the multivariate analysis due to missing data. Further expanding the sample size may help to obtain meaningful results.

Our study found increased rates of CMV infection in patients who received glucocorticoids and immunosuppressive agents. These results are similar to those of the majority of studies [25, 26]. In 2017, Shukla [27] et al. performed a meta-analysis and reported that exposure to corticosteroids (CS) (12 studies, 1180 patients, 52.3% exposed; OR, 2.05; 95% CI, 1.40–2.99) and thiopurines (14 studies, 1273 patients, 24.1% exposed; OR, 1.56; 95% CI, 1.01–2.39) was associated with increased risk of CMV activation. However, some of the studies included in this review did not clearly identify the severity of UC. Meanwhile, this meta-analysis did not evaluate the different influence of mild, moderate or large dose of glucocorticoids on CMV infection. Our results showed that patients who used large dose of steroids was significantly higher in the active CMV infection group than in the non-CMV infection group. No difference was found in mild or moderate dose of steroid. Therefore, the OR value of steroids and immunosuppressive agents in moderate to severe UC might be different to Tushar et al. reported. Besides, the retrospective case-control nature of this study might cause deviation in conclusion. Perspective cohort studies will be required for further investigation.
Similar to the results of another study [28], we did not find an increased risk of CMV infection due to the use of tumor necrosis factor (TNF) inhibitors because TNF inhibitors suppress TNF, an important cytokine that promotes CMV reactivation.

After removing confounding factors from the multivariate analyses, high-dose glucocorticoid treatment and immunosuppressive agents were shown to be independent risk factors for CMV infection in UC patients, increasing the risk of CMV infection in UC patients by 13.55-fold and 11.23-fold, respectively. Therefore, CMV infection should be strictly screened and monitored in these cases. Meanwhile, unnecessary long-term treatment with glucocorticoids at a high dose and immunosuppressive agents should be avoided.

Relatively few studies on the risk of CMV infection in UC patients with eosinopenia have been published. The eosinophil results are another highlight of our study, as the risk of CMV infection in UC patients was shown to decrease by 80.8% (1–0.192) with every 0.1*10^9/L increase in the peripheral blood eosophil level. In general, more attention should be paid to an increased eosinophil level because this phenomenon can promote gastrointestinal inflammation and the release of cytokines, chemical factors, and lipid regulators. An increase in eosinophils is also associated with IBD and some gastrointestinal diseases. Studies [29] in recent years have shown that eosinophils, a component of the innate immune system, have the capacity to respond to pathogen-related molecules and are closely associated with infection, and a significant reduction in peripheral blood eosinophil numbers usually occurs during the clearance of infection. In addition, eosinopenia is associated with acute infection [30], and studies [31, 32] have also shown that a reduction in eosinophils is a sensitive and reliable indicator for distinguishing between infection- and noninfection-related sepsis in intensive care units (ICUs).

The multivariate analyses suggested the following: long-term treatment with glucocorticoids at a high dose and immunosuppressive agents should be avoided; patients’ normal immune statuses should be maintained; Ig treatment should be properly applied for severe infections; and UC patients with low eosinophil levels should be monitored for CMV infection. Furthermore, patients with CMV infection showed lower serum albumin levels, which was probably due to severe inflammatory process (present as high hsCRP levels) and insufficient intake. A few studies [31, 33, 34] have indicated that albumin is a nutritional and inflammatory marker that reflects the potential for infection or disease activity. However, the effect of treatment targeting at increasing albumin in CMV infection has not been fully illustrate. Further studies are needed to investigate the role of albumin intervention in CMV infection in UC patients.

The limitation of this study is that due to its case-control nature, whether the indicators are the causes or results of CMV infection cannot be determined. For example, we found CMV group to have significantly higher use of high dose steroids, eosinopenia, elevated CRP. However, explanation remains that patients with more severe UC, which are more likely to be on high dose steroids, which ultimately are the patients with higher seropositivity for CMV. Although multivariate analysis showed that high dose steroids and eosinopenia are both independent risk factors for CMV infection in active UC, cohort studies will be required for further confirm and investigation. Moreover, this study discussed CMV infection in active UC but did not detailly discussed CMV colitis. Further studies are needed to specifically investigate the risk factors of CMV colitis in active UC. Meanwhile, other aspects (like genetics, hormonal changes and stress) which could contribute to CMV infection were not identified in this study. The influence of these aspects remains to be discussed in further studies. Besides, due to missing data, immunoglobulin was not included in the multivariate analysis. Further prospective studies are needed to better explore the role of immunoglobulin and compliment in CMV infection in active UC.

In summary, CMV infection may occur at the active stage of UC due to changes in the immune status or disease condition; in turn, CMV infection aggravates the condition of UC patients, making the inflammatory disease difficult to control. For patients with extensive UC, treating inflammation, correcting anemia and hyponatremia, improving immunoglobulin function and monitoring low serum and eosinopenia levels may help prevent CMV infection and lead to a better prognosis. Furthermore, the molecular mechanisms underlying the association between Ig, eosinopenia and UC combined with CMV infection are worthy of further study.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12876-020-01434-5.

**Additional file 1** Supplementary Table 1 Clinical Manifestations of Patients Satisfying Different Diagnostic Criteria.

**Abbreviations**

CMV: Cytomegalovirus; UC: ulcerative colitis; TNF: Tumor necrosis factor; ICUs: Intensive care units; ECCO: The European Crohn’s and Colitis Organization; CMV pp65: HCMV pp65 antigen; qPCR: quantitative polymerase chain reaction; LAK: Lymphokine-activated killer; NK: Natural killer; Ig: Immunoglobulins; hsCRP: High-sensitivity C-reactive protein

**Acknowledgements**

The authors thank the data processing staff in the Peking Union Medical College Hospital who collected the data, which formed the basis of this article.
Disclosures
None of the authors have any potential conflicts (financial, professional, or personal) that are relevant to the manuscript. The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ contributions
JQ conceptualized and designed the study. HY designed the study and drafted the manuscript. HY, KW, HZ, QO, YM, FG, NH, KZ, JS, JL, PZ, YL, JL, XW, YY, CC, YP and MC participated in data acquisition and statistical analysis. All authors critically revised the manuscript and agreed to be fully accountable for ensuring the integrity and accuracy of the work. All authors read and approved the final manuscript.

Funding
This work was supported by Health Research & Special Projects Grant of China (nos. 201002020 and 201502005) (Funder: JH), the National Natural Science Fund (81570505) (Funder: HY), and the Ministry of Science and Technology of China (2015CB943203) (Funder: JH and HY).

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All patients participating gave written informed consent and authorization.

Ethics approval
The corresponding author on reasonable request.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Consent for publication
Not Applicable.

Competing interests
The authors have no competing interests to declare.

Author details
1Department of Gastroenterology, Peking Union Medical College Hospital & Chinese Academy Medical Science Ethics Committee (IRB number: S-703).
2Department of Gastroenterology, Peking University First Hospital, Beijing, China.
3Department of Gastroenterology, Beijing Friendship Hospital, Beijing, China.
4Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
5Department of Gastroenterology, Beijing Chao-Yang Hospital, Beijing, China.
6Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
7Department of Gastroenterology, Jiangsu Province Hospital, Nanjing, China.
8Department of Gastroenterology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
9Department of Gastroenterology, Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, China.
10Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
11Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
12Department of Gastroenterology, General Hospital of Nanjing Military Region, Nanjing, China.
13Department of Gastroenterology, General Hospital of Beijing Military Region, Beijing, China.
14Department of Gastroenterology, Peking University People’s Hospital, Beijing, China.
15Department of Gastroenterology, Peking University First Hospital, Beijing, China.
16Department of Gastroenterology, Beijing Friendship Hospital of Capital Medical University, Beijing, China.
17Department of Gastroenterology, Beijing Hospital, Chinese Academy of Medical Sciences, Beijing, China.
18Department of Gastroenterology, Beijing Capital Medical University, Beijing, China.
19Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China.
20Department of Gastroenterology, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China.

Received: 12 April 2020 Accepted: 21 August 2020 Published online: 05 September 2020

References
1. Goodgame RW. Gastrointestinal cytomegalovirus disease. Ann Intern Med. 1993;119(9):924–5.
2. Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virology. 2013;1043.
3. Kandell A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101(12):2875–87.
4. Kim JJ, Simpson N, Klipfel N, Debrose R, Barr N, Laine L. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010;55(4):1059–65.
5. Mioni C, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colectomy. Dig Liver Dis. 2005;37(6):418–23.
6. Kim JW, Boo SJ, Ye BD, et al. Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J Crohns Colitis. 2014;8(7):693–701.
7. Zagórowicz E, Bugajski M, Wieszczcy P, Pietrzk M, Magdziak A, Morz A. Cytomegalovirus infection in ulcerative colitis is related to severe inflammation and a high count of Cytomegalovirus-positive cells in biopsy is a risk factor for colectomy. J Crohns Colitis. 2016;10(10):1205–11.
8. Wada Y, Matsu i T, Matak a H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46(10 Suppl):S59–65.
9. Harbord M, Elakim R, Betterw ton D, et al. Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017;11(12):1512.
10. Department of inflammatory bowel disease CSoG. Consensus on diagnosis and Management of Inflammatory Bowel Disease. Chin J Dig. 2018;3(3):173–90.
11. Truelove SC, Wits L. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041–8.
12. Colombel JF, Loufis EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99(5):878–83.
13. Yang H, Zhou W, Lv H, et al. The association between CMV Viremia or endoscopic features and Histopathological characteristics of CMV colitis in patients with underlying ulcerative colitis. Inflamm Bowel Dis. 2017;23(5):814–21.
14. Kim YS, Kim YH, Kim JS, et al. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. Gut Liver. 2014;8(6):643–7.
15. Lee HS, Park SH, Kim SH, et al. Risk factors and clinical outcomes associated with Cytomegalovirus colitis in patients with acute severe ulcerative colitis. Inflamm Bowel Dis. 2016;22(4):912–8.
16. Sager K, Alam S, Bond A, Chinnappan L, Probert CS. Review article: cytomegalovirus and inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(8):725–33.
17. Dennis EA, Smythies LE, Grabski R, et al. Cytomegalovirus promotes intestinal macrophage-mediated mucosal inflammation through induction of Smad7. Mucosal Immunol. 2018;11(6):1694–704.
18. Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004;10(3):245–50.
19. Cusano AI, Thies HL, Sigel FP, Dreisbach AW, Maesaka JK, Hyponatrema in patients with acquired immune deficiency syndrome. J Acquir Immune Defic Syndr. 1990;3(10):949–53.
20. Sarmiento E, Fernández-Yáñez J, Muñoz P, et al. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease. Int Immunopharmacol. 2005;5(5):197–201.
21. Sarmiento E, Rodriguez-Molina J, Muñoz P, et al. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation. Transplant Proc. 2005;37(9):4046–9.
22. Zhou LFF, Jiang J, et al. Changes of immunity function in cytomegalovirus infection. Immunol J. 2003;19(1):59–64.
23. Rai T, Wu X, Shen B. Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3(2):115–21.
24. Klemola T, Savilahki E, Koskimies S. Transient IgA and IgM deficiencies are frequent in children with ulcerative colitis. Eur J Pediatr. 1988;147(2):184–7.
25. Domènech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14(10):1373–9.
26. Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol. 2004;28(3):365–73.
27. Shukla T, Singh S, Tandon P, McCurdy JD. Corticosteroids and Thiopurines, but not tumor necrosis factor antagonists, are associated with Cytomegalovirus reactivation in inflammatory bowel disease: a systematic review and meta-analysis. J Clin Gastroenterol. 2017;51(5):394–401.
28. Pillet S, Jarlot C, Courault M, et al. Infliximab does not worsen outcomes during flare-ups associated with Cytomegalovirus infection in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21(7):1580–6.
29. Hogan SP, Waddell A, Fulkerston PC. Eosinophils in infection and intestinal immunity. Curr Opin Gastroenterol. 2013;29(1):7–14.
30. Bass DA. Behavior of eosinophil leukocytes in acute inflammation. II. Eosinophil dynamics during acute inflammation. J Clin Invest. 1975;56(4):870–9.
31. Shaaban H, Daniel S, Sison R, Slim J, Perez G. Eosinopenia: is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? J Crit Care. 2010;25(4):570–5.
32. Abidi K, Khoudri I, Belayachi J, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Crit Care. 2008;12(2):R59.
33. Levin A, Yaari S, Stoll R, Caplan O, Wolf DG, Israel E. Diagnosis of Cytomegalovirus infection during exacerbation of ulcerative colitis. Digestion. 2017;96(3):142–8.
34. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and Management of Ulcerative Colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–84.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.